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of completion of radiotherapy in both study arm and placebo 
arm and reported. 2 patients progressed during therapy and 
were not included in analyses and two patients discontinued 
the intervention. A per protocol analyses was done. 
 
 
Results: At analysis there were 50 patients in each arm. The 
severity of clinical proctitis was found to be similar in both 
groups of patients with 12.2 % of patients experiencing 
toxicity of grade 2 and above in digestible starch group 
versus 14.6% in the resistant starch group. Functional 
proctitis was similarly graded and it was found that 16.3 % 
patients in digestible starch group experienced toxicity 
against 10.2 % patients in the amylase resistant starch group. 
This difference was seen at 4th week and continued in the 
subsequent weeks till the end of radiation. Both groups had 
similar reported toxicity at 6 weeks post intervention. Both 
groups were also found to have similar incidence of grade 2 
and above diarrhea. The non-digestible starch group was 
found to have 8% incidence as compared to 2% in the other 
group at the 5th and 6th week. The short chain fatty acid 
concentrations were found to be not significantly different in 
the groups at any point. 
 
 
Conclusion: The study failed to demonstrate a benefit in 
administration of resistant starch in excess of normal diet to 
patients receiving pelvic radiotherapy. This may be 
postulated to be due to concurrent use of chemotherapy and 
decrease in intestinal probiotics. 
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Purpose or Objective: To compare treatment outcomes in 
locally advanced cervical carcinoma (LACC) patients treated 
with neoadjuvant chemoradiation followed by radical surgery 
(surgery group: SG) versus radical chemoradiation plus 
brachytherapy boost (control group: CG). Results in terms of 
local control (LC), metastases-free survival (MFS), disease 
free survival (DFS) and overall survival (OS) were compared. 
 
Material and Methods: Seventy-six patients with LACC (SG) 
were matched to 76 patients (CG) with respect to age, 
histology and stage. Matching was performed without 
knowledge of outcomes. Patients characteristics are 
summarized in Table 1. The median FU was 35 months 
(range: 2-107) for SG and 29 months (range: 1-125) for CG, 
respectively. 
 
 
Results: At univariate analysis no significant differences 
between the two groups were recorded. Two-year and 5-year 
LC were 77.6% and 71.0% for SG and 76.1% and 70.3% for CG 
(p=0.8), respectively. Two-year and 5-year MFS were 79.3% 
and 70.8% for SG and 78.8% and 78.8% for CG (p=0.6), 
respectively. Two-year and 5-year DFS were 71.9% and 61.6% 
for SG and 66.1% and 61.0% for CG (p=0.8), respectively. 
Two-year and 5-year OS were 90.9% and 84.4% for SG and 
90.3% and 69.9% for CG (p=0.4), respectively. 
 
Conclusion: The two treatment approaches achieved 
comparable outcomes in patients with locally advanced 
cervical carcinoma. Further analyses are needed to compare 
the toxicity profile of these two treatment strategies. 
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MR-PET is an advanced hybrid imaging method giving both 
structural, functional, molecular and biochemical information 
simultaneously or almost simultaneously. There are still 
challenges, not only with the attenuation correction, but also 
with performance of the examination and timing of the MR 
and PET acquisition.  
